RaiseForge
Capital Intelligence for Life Sciences
A capital intelligence platform built on real fundraising execution, powered by founder-first AI that improves how biotech capital is allocated—not just how it is raised.
Request Access
The Problem
Biotech capital exists in abundance- but it is systematically gated, misaligned, and chronically underutilized. The result: promising science dies not from lack of capital, but from lack of connection.
Strong Companies Fail
Misaligned investors derail promising companies, even when the science is sound and the opportunity is real.
Fragmented Diligence
Investors rely on closed networks and incomplete data, missing high-quality deals that fall outside their immediate orbit.
Capital Sits Out
New and emerging capital sources are excluded by complexity- unable to navigate a market built on opaque, unstructured information.
The issue is not access to capital or quality of science — it is the lack of structured connection between the two.
The Insight
Biotech fundraising has always been founder-driven—pitch decks, warm intros, roadshows. But outcomes are never determined by founders alone. They are determined by investor decision-making: how investors discover, evaluate, and ultimately act on opportunities.
The entire infrastructure of the market is built to help founders pitch—yet there is no system optimizing the investor side of the equation. RaiseForge solves this by structuring both sides of the market—starting with how companies are prepared and presented through guided fundraising workflows, and extending through how investors discover and act. Every interaction captures how capital actually moves — not just who raises it.
That is the gap RaiseForge was built to close.
The Solution
RaiseForge structures companies during the fundraising process and transforms them into opportunities investors can reliably evaluate and act on.
Powered by dual AI layers—one for data ingestion and normalization, the other for analysis and workflow orchestration—the platform turns raw inputs into structured, comparable, and investable opportunities.
Structured
Company data pulled from disparate sources (decks, financials, clinical docs, grants) and normalized into a consistent, diligence-ready format that eliminates noise and enables direct comparison.
Comparable
Every opportunity benchmarked against the market and investor criteria, delivering consistent scoring and relative merit in real time.
Investable
Clear execution pathways and investor alignment reduce friction and accelerate movement from evaluation to capital deployment.
Product
Three integrated engines form the RaiseForge platform. The first builds the proprietary dataset that powers everything else.
1
Fundability Engine
Standardizes raw founder and company data into structured, investor-ready profiles through guided fundraising workflows. This founder-first AI intelligence generates the proprietary dataset that powers all downstream analysis and matching.
2
Investor Discovery Engine
Investors pull deals based on proprietary fit signals—stage, thesis, therapeutic area, and capital capacity—surfacing opportunities they can act on immediately.
3
Capital Orchestration
Supports end-to-end execution pathways—from initial match to term sheet—coordinating diligence, communication, and deal progression.
Why Investors Pay
Institutional investors face a consistent problem: too many opportunities, too little structure. RaiseForge delivers what no existing tool provides—biotech deals that are ready to evaluate.
Structured Deal Clarity
No more digging through inconsistent decks. Every opportunity arrives in a normalized, comparable format.
Faster Evaluation
Reduce time-to-decision dramatically by eliminating the manual work of early-stage diligence.
Expanded Access
Surface high-quality opportunities outside closed networks—deals investors would otherwise never see.
Why Founders Participate
Founders engage because RaiseForge helps them raise capital more effectively — not just gain visibility.
Right-Fit Capital
Matched to capital whose thesis, stage focus, and capital capacity genuinely align—dramatically increasing the probability of a productive conversation.
Credible, Structured Visibility
A standardized profile signals institutional readiness. Founders who enter the platform look like companies that are prepared—because they are.
Actionable Feedback
Real-time engagement data—who viewed, who passed, who engaged—transforms a black box into a feedback loop that sharpens positioning and strategy, and informs the founders competitive position.
Founders participate because RaiseForge improves their probability of raising capital — while their activity generates the structured dataset that powers the investor intelligence platform.
The Data Moat
Every interaction on RaiseForge feeds a proprietary closed-loop intelligence system. Unlike static databases or one-directional platforms, RaiseForge improves with every deal, every signal, every outcome—compounding a durable competitive advantage that is structurally difficult to replicate.
RaiseForge captures how capital actually moves — not just who raises it.
Investor Behavior
What investors view, skip, flag, and fund—captured at every step of the discovery and evaluation journey.
Match Quality
Continuous calibration of fit signals as investor preferences and market conditions evolve in real time.
Funding Outcomes
Closed-loop outcome data ties every match to a result—building the only training set that links investor intent to capital deployed.
Business Model
RaiseForge starts with execution-first founder onboarding that creates supply, then monetizes demand through investor-facing intelligence products. The platform is built on a supply-and-demand flywheel: founders contribute structured deal flow at no cost, while investors pay for curated, actionable access
Investor SaaS (Primary)
Recurring subscription revenue from institutional and emerging fund managers accessing the discovery and evaluation platform.
White-Label AI
Licensing the intelligence layer to platform partners—accelerators, banks, family offices—as an embedded capital intelligence tool.
Marketplace Services
Premium services for founders and investors transacting within the ecosystem— financial services, data rooms, legal, diligence support, branding/early-stage marketing.
Success Fees (Future)
Participation in closed transactions as platform scale and outcome attribution mature into a defensible fee model.
The Flywheel
Founders = Supply & Demographic Mapping (generated through real fundraising execution) No-cost onboarding enables founders to engage in real fundraising execution, generating a continuously evolving dataset of "scored" companies.
This creates a structured, high-quality supply layer and a mapped landscape of biotech opportunities that fuels investor engagement.
SaaS & Marketplace Service Based Revenue Paying subscribers unlock access to structured, comparable biotech deal flow
They receive proprietary scoring that benchmarks how their funding decisions compare to similar investors—delivering insight into performance, positioning, and competitive edge.
Investors = SaaS & Score Comparisons Paying subscribers unlock access to the most structured and comparable biotech deal flow available anywhere.
They also receive a proprietary score that benchmarks how their funding decisions compare against similar investors in the marketplace—providing clear insight into performance, positioning, and competitiveness.
More founders → better investor ROI → more investors → stronger capital access→ continuous interactions → network effects compound.
Product Roadmap & Funding Strategy
Our strategic roadmap outlines key product development phases and corresponding funding requirements to achieve our vision.
1
Year 1: Foundation & MVP
Launch Fundability Engine and full orchestration. Release medium-weight Investor Tool (public data, 8-pillar scoring) and initial Elite Service Provider Marketplace. Initial focus on fundraising-driven onboarding to rapidly build the proprietary dataset and validate investor demand.
2
Years 2-3: Expansion & SaaS
Evolve Investor Tool into a full SaaS product. Expand Marketplace with more vendors and higher attach rates. Initiate white-label hosting partnerships for broader reach.
3
Years 3-5: Scale & Premium Data
Scale our brokerage arm for deal execution. Develop and offer premium data products, cementing our position as a leader in biotech capital intelligence.
Funding Tranches
Tranche 1: $350K – $400K
(May 2026) Funds MVP build, founding engineer, marketplace launch, legal/compliance, and first pilot cohort.
Tranche 2: $1.2M – $1.3M
(Post-pilots) Completes full APIs, expands founder & investor platforms, and initiates white-label hosting discussions.
Tranche 3: $1.95M – $2.1M
(Scale Phase) Delivers full investor SaaS, doubles down on marketplace growth, and prepares brokerage arm and premium data products.
New Total Funding Need: $3.5M – $3.8M
The Vision
The Operating System for Biotech Capital Formation
RaiseForge is building the foundational infrastructure that every participant in life sciences capital markets will depend on—from first-time founders to the most sophisticated institutional allocators on the planet.
Expand Who Can Invest
Lower structural barriers for emerging managers, family offices, and international capital to participate confidently in biotech—unlocking pools of capital that today sit on the sidelines.
Improve Capital Outcomes
Better matching, faster evaluation, and closed-loop intelligence drive superior returns for investors and higher success rates for the companies they back.
Unlock New Markets
As the platform scales, RaiseForge creates the data layer that enables entirely new instruments, syndication models, and cross-border capital flows in life sciences.
The Team
Technical infrastructure + commercial execution → built to scale biotech capital markets
Bryan Knipe— Founder & CEO
Platform Strategy | Capital Ecosystems | Product Architecture
  • Built and scaled a $200M+ managed analytics business at Optum with full P&L responsibility
  • Founder of TriPinnacle Advisors, where he has led and supported multiple successful life-sciences capital raises, including multiple completed Reg CF and Reg D transactions
  • Currently directing RaiseForge's product strategy, data architecture, and full technical development in close partnership with specialized AI infrastructure and engineering teams
Marsha L. Hartman— Co-Founder
Commercial Leader | Cell Analysis | Biotech Scaling
  • Market-shaping commercial expert in cell analysis and cytometry
  • Proven track record Series A through public company execution
  • Innovator: first to launch dried reagents for clinical FACS, early leader in spectral technologies, current seed stage CEO
  • Built and led high-impact collaborations across the biotech ecosystem, including record setting SCIENCE magazine collab
  • Winner's Circle ($10M+) and commercial leadership driving >$100M in impact